Bio-Rad Laboratories (NYSE:BIO – Get Free Report) and Jin Medical International (NASDAQ:ZJYL – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Bio-Rad Laboratories and Jin Medical International, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bio-Rad Laboratories | 1 | 3 | 1 | 0 | 2.00 |
| Jin Medical International | 1 | 0 | 0 | 0 | 1.00 |
Bio-Rad Laboratories currently has a consensus price target of $303.33, indicating a potential downside of 0.84%. Given Bio-Rad Laboratories’ stronger consensus rating and higher possible upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Jin Medical International.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bio-Rad Laboratories | $2.58 billion | 3.17 | $759.90 million | $6.07 | 50.40 |
| Jin Medical International | $20.69 million | 1.23 | $1.19 million | N/A | N/A |
Bio-Rad Laboratories has higher revenue and earnings than Jin Medical International.
Volatility and Risk
Bio-Rad Laboratories has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Jin Medical International has a beta of 7.23, indicating that its share price is 623% more volatile than the S&P 500.
Insider and Institutional Ownership
65.2% of Bio-Rad Laboratories shares are owned by institutional investors. 30.3% of Bio-Rad Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Bio-Rad Laboratories and Jin Medical International’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bio-Rad Laboratories | 6.52% | 3.56% | 2.49% |
| Jin Medical International | N/A | N/A | N/A |
Summary
Bio-Rad Laboratories beats Jin Medical International on 11 of the 12 factors compared between the two stocks.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
About Jin Medical International
Jin Medical International Ltd. engages in the design, development, manufacturing, and sale of wheelchair and other living aids products for people with disabilities or impaired mobility in China and internationally. It also offers oxygen concentrators and bathing machines. The company was founded in 2006 and is based in Changzhou, China. Jin Medical International Ltd. is a subsidiary of Jolly Harmony Enterprises Limited.
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
